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Abstract
Iron deficiency anemia (IDA) frequently occurs in patients suffering from inflammatory bowel
disease (IBD) and negatively impacts their quality of life. Nevertheless, the condition appears to
be both under-diagnosed and undertreated. Regular biochemical screening of patients with IBD
for anemia by the gastroenterology community has to be advocated.
Oral iron is a low cost treatment however its effectiveness is limited by low bioavailability and
poor tolerability. Intravenous (IV) iron rapidly replenishes iron stores and has demonstrated its
safe use in a number of studies in various therapeutic areas. A broad spectrum of new IV iron
formulations is now becoming available offering improved tolerability and patient convenience
by rapidly restoring the depleted iron status of patients with IBD. The following article aims to
review the magnitude of the problem of IDA in IBD, suggest screening standards and highlight
existing and future therapies.
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Anemia is a frequent extra-intestinal manifestation in in-
flammatory bowel disease (IBD) known to negatively impact
physical quality of life.1,2 Anemia has been even revealed as
a co-morbid condition that contributes to death of patients
with IBD.3 Though it seems logical that anemia would also
increase the rate of hospitalization and medical costs in IBD
respective data are still lacking.
Iron deficiency (ID) and anemia of chronic diseases (ACD)
are the most common causes of anemia in IBD. Therefore,
together with an adequate control of underlying inflammation
iron replacement therapy should start as soon as ID or anemia
is detected to attain a normal iron status and Hb.4 This results
in improvement in the patients' quality of life independent of
changes in disease activity.1,5 Although efficient therapeutic
options have been developed for the treatment of IBD-
associated anemia, treating this manifestation appears to
remain of low priority for gastroenterologists.6,7
This review aims to give some guidance on how to address
ID in patients with IBD including screening procedures,
therapeutic options and their potential outcomes. Further-
more the review discusses potential clinical benefits of a
new generation of IV iron preparations in the treatment of
IBD.2. Prevalence and etiology of anemia in IBD
Prevalence rates of anemia in IBD are widely varying from 6
to 74%, which also appears to reflect differences in the stan-
dards of screening and treatment as well as in the settings
under which patients were studied.4 Anemia is reported
more frequently in hospitalized patients with IBD and occurs
more frequently in Crohn's disease (CD) as compared to
ulcerative colitis (UC).8,9 It also appears that hemoglobin
concentrations increase in the years after diagnosis which
may be explained by the remission of disease following suc-
cessful medical or surgical treatment.9
Anemia in IBD is mainly the expression of a mixed patho-
genesis with ID and ACD posing the most prominent factors
often existing in parallel.10 Nevertheless, with a reported
prevalence of up to 90% ID is the most frequent cause.4 Iron
deficiency may be related to low dietary intake as well as
low intestinal bioavailability of iron, decreased internal
iron turn-over, and blood loss.11,12 Semrin and co-workerssuggested that inflammation may inhibit iron absorption as it
correlates with disease activity and markers of inflammation
in Crohn's disease.13 The accurate contribution of intestinal
blood loss as a source of ID has not been studied, although it is
supposed to pose a major component.9
On the other hand, the exact prevalence of ACD is un-
known.14,15 The etiology of ACD is ascribed to altered eryth-
ropoiesis and red cell survival. IBD patients may suffer from
functional iron deficiency (FID) due to iron retention in
macrophages driven by pro-inflammatory cytokines and
hepcidin. During an acute phase response hepcidin is induced
in the liver by IL-6 and reduces iron absorption from the
duodenum as well as iron recycling frommacrophages.16,17 In
addition, chronic inflammation has been suggested to de-
crease erythropoiesis either directly by IFN-gamma or be-
cause of decrease in the synthesis and the biological activity
of erythropoietin (EPO) induced by IL-1, IL-6, TNF-alpha, and
hepcidin.15,17
Finally, it must be borne in mind that there are other
frequent reasons for anemia in IBD patients. Vitamin B12
deficiency is commonly found in patients with IBD, particularly
after resection of the ileum andmay lead to hyperchromatosis
and macrocytosis.4,18,19 Prescribed medical treatment should
also be considered as a potential cause of anemia in patients
with IBD. Methotrexate and sulfasalazine interfere with the
absorption of folate and may mediate folate deficiency.18
Sulfasalazine may also induce hemolysis or bone marrow
aplasia. Thiopurines and methotrexate can induce bone
marrow toxicity in a minority of patients.43. Clinical manifestations and consequences of
iron deficiency
Symptoms and signs of ID even without anemia comprise
impaired physical performance, reduced cognitive function,
fatigue, headache, dizziness, shortness of breath, restless
legs syndrome, hair loss, angular stomatitis, glossitis, pica
and reduced libido.20 Other features include an increase in
complications during pregnancy, blunted thermoregulation,
and villous atrophy.16
IDA in addition has an impact on the immune status and
morbidity from infections. ACD is caused by iron retention
in macrophages. Phylogenetically this is an interesting
and potentially protective innate immune function of the
host because iron is a key growth and virulence factor for
431Diagnosis and treatment of iron deficiency anaemia in IBDmicrobes.17 Iron is also an essential component of many
enzymes. Iron is involved in immune effector pathways of
neutrophils and macrophages, e.g. formation of toxic hy-
droxyl radicals. Iron restriction affects B cell and T helper
cell proliferation and differentiation, and iron overload
leads to NK cell dysfunction.17 Additionally, high iron re-
duces the responsiveness of macrophages to IFN-γ resulting
in lower production of TNF-α.17
Another important aspect is the relationship between ID,
thrombocytosis and thromboembolism. It is recognized that
there is an increased risk of deep venous thrombosis and
thromboembolism in patients with IBD.21 Indeed this risk in
the younger age groups is 3–4 times higher. There is also
an increased risk of recurrent thromboembolism and IBD
independently increases this risk.22–26 Thrombocytosis in IBD
is a typical feature of active disease and appears to be
driven by acute phase responses of interleukins such as IL-6
dependent induction of thrombopoietin and increased levels
of IL-11.24,25,27–29 But iron deficiency in itself may lead to
thrombocytosis in IBD due to the expansion of the megakar-
yocyte lineage and accelerated differentiation.28,30 As to
whether IDA per se may be linked to an increased risk of
thromboembolic events independent of thrombocytosis re-
mains to be determined.
4. Differential diagnosis of anemia in IBD
IBD patients at risk of anemia are typically newly diagnosed
patients presenting with high disease activity and possibly
bleeding and UC patients with extensive disease.4 As anemia
is the most common extra-intestinal complication in IBD and
ID is the most prevalent cause of anemia in IBD, assessment
of the iron status is imperative. The World Health Organi-
zation defines anemia as a hemoglobin (Hb) concentra-
tion b12 g/dL (7.45 mmol/L) in non-pregnant women and
b13 g/dL (8.07 mmol/L) in men.31 These criteria apply also
in IBD.6 However, there is no single biomarker to diagnose
ID. Assessment of iron status at a low cost involves simple
measurements and allows in most cases differentiating
between IDA, ACD and the combination of the two (Table 1).
Basic laboratory screening for anemia in IBD should
comprise Hb, full blood counts (including reticulocytes) and
assessments of total store of body iron with serum-ferritin
(S-ferritin), of the iron available to the bone marrow
(erythron) with transferrin saturation (TfS), and of the level
of inflammation by means of C-reactive protein (CRP).6
Further testing for causes of anemia in IBD could comprise
vitamin B12, folic acid, haptoglobin, lactate dehydrogenase,
and serum creatinine in order to exclude potential hemol-
ysis or renal disease, which in itself causes anemia.6 Patients
in clinical remission should be screened at least every
12 months, whereas patients with active disease at leastTable 1 Laboratory findings in anaemia – basic work up.
Laboratory measures IDA ACD IDA and ACD
Hemoglobin ↓ ↓ ↓
CRP Normal ↑ ↑
Serum ferritin ↓ ↑ ↑ or normal
Transferrin saturation ↓ ↓ ↓every 3 months or at shorter intervals depending upon iron
status.32
4.1. Iron deficiency without anemia
A normal Hb level does not exclude ID, because individuals
with normal body iron stores must lose a large portion of
body iron before the Hb falls below the laboratory definition
of anemia. In non-anemic IBD patients, the most important
clinical clue of ID is the symptom of chronic fatigue as iron is
required for the enzymes involved in oxidative metabolism.
However, as an unspecific symptom it is of little screening
value.33
A normal Hb level with a mean corpuscular hemoglobin
(MCH) in the lower limit of normality (normal range:
28–35 pg) or an increased red cell distribution width (RDW,
normal range: 11–15) point to mild ID without anemia.34
Interestingly, RDW has been reported as an independent
indicator for predicting disease activity in patients with CD
and UC without anemia.35,36 However, in every day clinical
practice, the main laboratory finding is a low ferritin level
(1 ng/mL of serum ferritin corresponds to approximately
8 mg of stored iron). Thus, measurement of ferritin provides
the most useful indirect estimate of body iron stores, and ID
can be defined by a ferritin level b30 ng/mL in the absence
of inflammation (e.g., normal serum concentrations of
C-reactive protein [CRP] and/or normal erythrocyte sedi-
mentation rate). In the presence of inflammation, a normal
ferritin level (acute phase reactant) does not exclude ID, and
TfS should be also measured. Thus, in the presence of
inflammation, functional ID should be defined by low TfS
(b20%) and normal ferritin concentrations (N100 ng/mL),
whereas low TfS (b20%) and intermediate ferritin values
(30–100 ng/mL) suggest absolute ID.16 Functional ID may
also occur in response to the therapeutic use of erythopoiesis
stimulating agents, which place a significant demand on iron
stores that may surpass the iron-release capacity of the
RES.37
ID can also be defined by a ferritin index N3.2 (N2.0 if CRP
N5 mg/L). The ferritin index is the ratio between the soluble
transferrin receptor (sTfR; truncated form of the transferrin
receptor whose serum concentration is proportional to the
total amount of surface transferrin receptors) and the log
ferritin, and reflects the iron supply for erythropoiesis.38
Reticulocyte Hb content (CHr) has also been suggested to be
able to differentiate IDA and ACD. It measures the Hb con-
tent of reticulocytes and is a direct measure of available iron
for erythropoiesis. CHr has a high sensitivity and specificity
for diagnosing iron deficiency and is less affected by in-
flammation than transferrin saturation and ferritin, but so
far no data are available from IBD.38
4.2. Iron deficiency anemia
Patients should be considered to suffer from IDA when they
presentwith lowHb (men b13 g/dL andwomen b12 g/dL), TfS
(b20%) and ferritin concentrations (b30 ng/mL) but no signs of
inflammation.33 A low mean corpuscular Hb (MCH b27 pg), or
better a low reticulocyte Hb content (CHr b28 pg), rather than
mean corpuscular (MCV b80 fL) became the most important
red cell markers for detecting ID in circulating red blood cells
IDA1 ACD + ID ACD2
Transferrin saturation <20%
Hb <12 g/dL - <13 g/dL
+ MCH <27 pg 
Ferritin Ferritin
Figure 1 Algorithm for diagnosis of iron deficiency anaemia in
IBD.
432 W. Reinisch et al.(Fig. 1). MCV is a reliable and widely available measurement
but is a relatively late indicator in patients who are not
actively bleeding.34 Although sTfR levels are high or very high
in uncomplicated IDA, as is the ferritin index, they are not
usually required for the diagnosis.34
4.3. Anemia of chronic disease
Patients should be considered to suffer from ACD, also called
anemia of inflammation, when they have: 1) evidence of
inflammation (e.g. increased serum CRP level) 2) a Hb
concentration b13 g/dL for men and b12 g/dL for women,
and 3) a low transferrin saturation (TfS b20%), but normal or
increased serum ferritin concentration (N100 ng/ml; Fig. 1).
In the presence of intermediate serum ferritin concentration
(30–100 ng/ml), confirmation of ACD will be given by the
ferritin index plot as a sTfR/log ferritin ratio b2 with normal
CHr (Table 2).38–41
4.4. Anemia of chronic disease with absolute
iron deficiency
Patients should be suspected to have ACD with absolute iron
deficiency when they have: 1) a chronic inflammation, 2) a Hb
concentration b13 g/dL for men and b12 g/dL for women,
and 3) low transferrin saturation (TfS b20%) with a serum
ferritin concentration N30 and b100 ng/ml (Fig. 1). Confir-
mation of ACD+ID will be given by the ferritin index plot as a
sTfR/log ferritin ratio b2 with a CHr b28 pg (Table 2).38–41
Supplementary laboratory tests may need to be taken into
consideration for the differential diagnosis between IDA and
ACD (Table 2).20,42 Recently, it has been shown that hepcidin
levels were significantly higher in IBD patients comparedTable 2 Laboratory findings in anaemia — supplementary work u
Laboratory measures IDA
sTfR ↑
sTfR-Ferritin index High (
Mean corpuscular volume ↓
Reticulocyte Hb content (CHr, pg) b28
Percentage of hypochromic red blood cells N5
Zinc protoprophyrin (μmol/mol heme) N40
Cytokine levels Norma
Hepcidin ↓with healthy controls, whereas those of prohepcidin levels
were significantly lower.43 In addition, significant correla-
tions of hepcidin with ferritin, CRP and disease activity of IBD
were found. This finding suggests a substantial role of these
two hormones in the development of anemia in IBD, and the
potential role of hepcidin measurement for its differential
diagnosis. In this regard, Thomas et al. have shown that
hepcidin may replace the ferritin index for confirmation of
combined IDA and ACD, which may be given by the hepcidin
plot as a hepcidin N4 nmol/L with a CHr b28 pg.44
In addition some hematological indices may help in the
diagnosis of iron deficiency in ACD, but which are available
in specific hematology analyzers only. Hypochromic red
blood cells (HYPO) are reported by the Bayer Advia 120
hematology analyzer (normal value b5%).45 The Sysmex
XE-2100 hematology analyzer determines RET-Y, which can
be considered the reticulocyte hemoglobin equivalent
(RET-He), as well as RBC-Y, which can be considered as the
erythrocyte hemoglobin equivalent.46 The clinical utility of
these new indices in the diagnosis of ID is currently under
evaluation.47 Finally, the Beckman-Coulter LH 780 deter-
mines different red cell parameters, such as RDW, Red
blood cell Size Factor (RSF), Reticulocyte Distribution Width-
Coefficient of Variation (RDWR-CV), and Reticulocyte Distri-
bution Width-Standard Deviation (RDWR-SD). In a recent
study, of 100 IBD patients and 102 healthy controls, high
values of RDW and low values of RSF were the best markers
for the diagnosis of IDA, whereas both RDWR-CV and RDWR-SD
were significantly correlated with disease activity and CRP
levels.485. Treatment options for ID in IBD
The prevalence of anemia in IBD has decreased over time,
reflecting the improved treatment modalities for IBD pa-
tients.10 However, in IBD patients consecutively seen and who
had blood test at an outpatient clinic during the years 1993
and 2003, Vijverman et al. observed that prevalence has only
decreased for mild to moderate, but not severe anemia in
an IBD population over the last 10 years.49 Therefore, IDA
remains a significant clinical problem, which requires careful
assessment and management in IBD.6 Unlike nephrologists to
whom administration of intravenous (IV) iron has become
routine in the management of anemia in patients with chronic
kidney disease (CKD), incorporation of iron therapy, particu-
larly in its IV formulations, to the treatment standards in IBD
appears to have progressed slowly.8,10 Only recently anemiap.
ACD IDA and ACD
Low (b1) ↑ or normal
N2) ↓ High (N2)
↓ or normal ↓ or normal
≥28 b28
b5 N5
b40 N40
l ↑ ↑
↑ ↑
Figure 2 Treatment and follow-up algorithm in moderate iron deficiency anemia and severe iron deficiency anemia, respectively.
(Abbreviations: Hb = hemoglobin, TDI = total-dose infusion, FCM = ferric carboxymaltose, LMWID = low molecular weight iron dextran,
ESA = erythropoiesis stimulating agent).
433Diagnosis and treatment of iron deficiency anaemia in IBDhas been recognized as an overlooked villain in IBD.50 This is
also reflected by the fact that guidelines for iron therapy
were not considered by the initial consensus proceedings from
the European Crohn's and Colitis Organization (ECCO). Very
recently, Auerbach and Ballard reviewed the history, phar-
macology, administration, efficacy, and toxicity of intrave-
nous iron within the Educational Program of the American
Society of Hematology. They clearly showed how intravenous
iron offers advantages over oral iron for the treatment of IDA
across a wide range of disease states associated with absolute
and functional ID. They also discussed the remaining concerns
about the acute safety profiles of the available preparations
and the potential for long-term toxicity with their repeated
administration.51
Since parenteral iron was first introduced for human use
in the 1930s, much progress and innovation has occurred.
Eighty years ago, iron, administered as an oxyhydroxide
complex, was toxic. This problem was circumvented with
the introduction of compounds containing iron in a core
surrounded by a carbohydrate shell, consisting of dextran,
gluconate, sucrose, or dextrin. The first dextran-containing
IV iron preparations (high molecular weight iron dextran,
HMWID), which were introduced in 1954, allowed for large
dose administration, but carried a risk of anaphylaxis, which
is of less concern with the later introduced low molecular
weight iron dextran preparation (LMWID) in 1991. Ferric
gluconate (1999) and iron sucrose (2000) were the first
available dextran-free iron preparations. Recently, three
newer IV iron preparations (ferumoxytol, ferric carboxy-
maltose and iron isomaltoside 1000) have become available
for which a test dose is no longer required and due to
the structure of the formulations higher doses of iron can
be delivered as a single dose administration. Nevertheless,iron reactions may occur with all IV iron preparations,
but are generally not thought to be immune mediated.
Table 3 summarizes the characteristics of the available IV
preparations.6. Iron therapy and the course of IBD
Iron supplementation should be considered in all iron deficient
patients with IBD and initiated in those in whom hemoglobin
concentrations fell below normal (Fig. 2). Because of its low
cost and non invasive method of administration oral iron at a
daily dose between 50 mg and 200 mg is the conventional
approach in patients with mild to moderate anemia (Hb
≥10 g/dL, ferritin b30 μg/L).7 Oral iron compounds are
mostly available as inorganic ferrous salts, sometimes com-
bined with vitamin C which enhances iron absorption.
However, gastrointestinal tolerability of oral iron is limited
and it may take two to three weeks for hemoglobin con-
centrations to increase, up to two months to achieve normal
values and at least six months to replenish iron stores.5 In
addition to the generally low bioavailability of oral iron,
intestinal absorption is further compromised in patients with
IBD due to an inflammation-driven blockade as outlined above.
There are other potential downsides associated with oral
iron therapy. Oral iron increases the severity of experimental
colitis and impacts the intestinal microbiom.52 The former is
also ascribed to redox reactions which lead to the production
of reactive oxygen species and mediate intestinal damage in
rodents.4,53–55 In a murine colitis model an increased preva-
lence of intestinal adenomas was observed after prolonged
treatment with oral but not parenteral iron.53,54 However,
the important question remains what the impact of oral iron
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434 W. Reinisch et al.on mucosal inflammation is in patients with IBD. From two
randomized controlled trials a potential effect of iron sup-
plementation on clinical disease activity could not be de-
lineated, although the studies were not adequately powered
to answer this question.56,57 Also the effect of oral iron on
colorectal carcinoma in humans remains controversial and
data on patients with IBD are missing.58–61
Data from eight clinical studies on the experience of IV
iron therapy for IDA in IBD comprising a total of 719 patients
showed that overall intravenous iron treated patients had
higher response rates compared to patients treated with oral
iron (Table 4).5,56,57,62–66 Additionally, it was found that
treatment discontinuation due to adverse events was lower
in patients treated with IV iron compared to patients treated
with oral iron.67 Thus, IV iron is more effective and better
tolerated than oral iron and is to be considered in patients
with severe anemia (Hb b10.0 g/dL), with intolerance or
inadequate response to oral iron and/or those with active
IBD. Intravenous iron administration is the route of choice
when simultaneous treatment with erythropoiesis stimulat-
ing agents (ESA) is considered.6
There has been much debate on whether low or high dose
intravenous iron is more efficient in rapidly replenishing iron
stores. Gisbert et al. reported a response rate in IBD patients
of 77% with iron sucrose 2×200 mg/week,5 whereas Kulnigg
et al. published an identical response rate of 77% in IBD
patients using ferric carboxymaltose at a maximum dose
of 1000 mg iron per infusion at 1-week intervals.56 These
studies were comparable in terms of Hb concentrations at
baseline being b10 g/dL and response being defined as an
increase in Hb of≥2 g/dL. However, the duration of the iron
sucrose study was 26 weeks as compared to only 12 weeks in
the ferric carboxymaltose trial.
More recently, the superiority of higher intravenous iron
doses was shown in a comparative clinical trial of the efficacy
and safety of standardized ferric carboxymaltose doses with
respect to individually calculated iron sucrose doses.68 After
12 weeks ferric carboxymaltose was superior with regard to
response rate, defined as an increase in Hb concentrations
of N2 g/dL (66.1% versus 54.1%), proportion of non-anemic
patients (72.8% versus 61.8%) and full adherence to the
treatment regimen (92.5% vs. 79.1%), whereas there was no
difference in treatment-related adverse events (13.9% vs.
11.3%). However, skin and subcutaneous tissue disorders
such as rash, dermatitis, and pruritus that were related to
the study drug occurred more frequently in the ferric
carboxymaltose group than in the iron sucrose group (3.7%
vs. 0.8%). Mean serum phosphate levels decreased from
baseline to week 2 in the ferric carboxymaltose group and
hypophosphatemia developed in 2.5% of patients in the ferric
carboxymaltose group. The mechanism of the decrease in
serum phosphate levels seen with ferric carboxymaltose is
unknown. Infusion site reactions were observed more fre-
quently in the iron sucrose group than in the ferric carboxy-
maltose group (2.5% vs. 0.4%) possibly because of the alkaline
pH of the preparation and the higher number of infusions in
the iron sucrose group.
The optimal target range for iron substitution has not been
studied specifically. Iron homeostasis is regulated at intake
and the bone marrow requires 20–30 mg/day for erythropoi-
esis, a demand which may increase to 50 mg/day in severe
anemia. Iron supplementation for erythropoiesis is optimal at
Table 4 Characteristics of the clinical trials involving IBD patients that compared IV iron administration with oral iron or no intervention included in this review.
Study year (ref) n Study design Compound Baseline Hb
(g/dL)
Total dose, mg (schedule) Duration
(weeks)
Response DCT
Gasche et al., 200162 103 Multicenter, open-label Iron sucrose ≤10.5 1200 mg (6×200 mg) 4 65% 0%
Bodemar et al., 200463 59 Retrospective Iron sucrose b12 Mean 1400 mg 8 60% 0%
(1–2×200 mg/week) 12 91%
Schröder et al., 200557 46 Multicenter Iron sucrose (22) b10.5 ♀ Mean 1418 mg 6 55% 4.5%
Randomized b11 ♂ (7 mg/kg+5×200 mg)
Open-label Ferrous sulfate (24) Mean 5600 mg 53% 20.8%
(100–200 mg/day)
García-López et al., 200664 70 Single center Iron sucrose b10.5 a Mean 920 mg Mean 5 67% 0%
Prospective (200–1800 mg) (1–9 )
Observational (200 mg/1–3 times a week)
Kulnigg et al., 200856 200 Multicenter Ferric ≤10 1000–1500 mg 12 77% 1.5%
Randomized Carboxymaltose (137) (1–2 infusions of 500–1000 mg)
Open-label Ferrous sulfate (63) 16800 mg 68% 7.9%
(200 mg/day)
Lindgren et al., 200965 91 Multicentre Iron sucrose (45) b11.5 Mean 1700 mg 20 66% 7%
Randomized (200 mg/1–2 weeks)
Investigator-blinded Ferrous sulfate (46) Mean 38400 mg 47% 22%
(200–400 mg/day)
Gisbert et al., 20095 100 Multicenter, open-label Iron sucrose (22) b10 Not reported 26 77% 0%
(2×200 mg/week if Hb b10)
Ferrous sulfate (78) N10 19000 mg 89% 5.1%
(106 mg/day)
Koutroubakis et al., 201075 50 Single center Low molecular weight b10 ♀ a 800–1600 4 23% 10%
Prospective Iron dextran b11 ♂ a Total dose infusion
Observational
Response: Hb ≥2 g/dL or normal Hb; DCT: discontinuation due to serious adverse events.
a Also those patients with no response or intolerance to oral iron, or with clinical need of quick recovery from anemia.
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436 W. Reinisch et al.TfS of 30–40% and serum ferritin of 400–500 μg/L and this
is particularly important for patients already being treated
for IDA. Over-supplementation could theoretically result in
iron deposition in parenchymatous organs. However, data
from patients with thalassemia suggest that this risk appears
negligible.69 An iron overload of the macrophages in the
reticulo-endothelial system may induce an over-expression of
ferroportin which may allow, via bypassing the hepcidin block
in ACD, an iron flow to the bone marrow.16 This could explain
the superiority of high intravenous iron supplementation in
IBD. In addition macrophage iron loading may inhibit pro-
inflammatory immune effector pathways.17,70 Nevertheless,
iron therapy is not recommended in sepsis because it may
potentially worsen the disease.
The aim of iron therapy is the normalization of iron stores
and ensuring the increase of Hb concentrations into the
normal range (Fig. 1).32 However, neither the optimal Hb
concentration which is to be achieved nor the preferred
approach on how to calculate the necessary iron dose has
been studied in detail in IBD. The Ganzoni formula captures
total body iron deficit in mg=(body weight in kg×[target
hemoglobin — actual hemoglobin in g/dL]×0.24)+500.71 The
formula is based on a hemoglobin target concentration of
15 g/dL, a hemoglobin iron concentration of 0.37%, a blood
volume making 7% of body weight and a demand of iron stores
of 500 mg. More recently, an alternative dosing scheme also
based on hemoglobin concentration and body weight has been
presented for dosing of ferric carboxymaltose. For a baseline
hemoglobin of N10 g/dL dosing was 1.0 g for patients with a
body weight less than 70 kg and 1.5 g for patients N70 kg. The
corresponding total doses for serum hemoglobin ≤10 mg/dL
were 1.5 g and 2.0 g.68 Mathematical models might be
utilized in the future not only to identify causes of anemia in
patients with IBD, but also to estimate the total iron dose
required to replenish deficient stores.72
To date treatment should strive for ferritin concentra-
tions of N100 μg/L. However, after intravenous iron treat-
ment reliable ferritin concentrations reflecting iron stores
should be measured as early as 8 weeks after therapy.32 An
increase in Hb is associated with improved quality of lifeFigure 3 The iron core is: (a) wrapped in a carbohydrate sh
(b) enmeshed in a matrix with interchanging iron and carbohydrate m
new preparations allows only a low level of free iron to circulate inscores and better cognitive functions in patients with IBD.
These changes are independent of disease activity.1,5
IDA is a recurrent problem, which requires continuous
attention and follow-up by the physician. A retrospective
analysis of 88 patients with IBD treated with IV iron±
erythropoietin revealed the frequent recurrence of anemia
within only months after supplementation.73 Thus, regular
controls, e.g. at 12 week intervals are advocated and re-
treatment initiated as soon as Hb concentrations or iron
parameters are below the levels indicated above. The exis-
tence of ID in asymptomatic patients with IBD should always
spur the suspicion of a physician on subclinical inflammatory
activity as the discrepancy between clinical symptoms and
endoscopic lesions is a well known phenomenon.7. New entries of iron supplementation
One of the putative concerns with IV iron administration has
been the issue of free (catalytic) iron reactions occurring
during the transportation of iron in the body. Recently, IV iron
formulations have been introduced in which this potential
problem is minimized due to a strongly bound iron carbohy-
drate complex. In both iron caboxymaltose and ferumoxytol
an iron core is wrapped in a carbohydrate shell that shields
the activity of ferric iron to the plasma (Fig. 3a). Only 2–3% of
the ferric iron in the administered dose passes directly to
transferrin in the plasma, whereas the whole complex is taken
up by macrophages in the reticulo-endothelial system (RES).
The iron complex is subsequently degraded and iron trans-
ferred to transferrin with a negligible free iron reaction. A
similar mechanism occurs for iron isomaltoside 1000 which
consists of a matrix with interchanging iron and carbohydrate
molecules (Fig. 3b).
These novel structures of the new IV iron formulations not
only reduce this risk of free iron reactions, but are also of
lower immunogenicity which allows treatment initiation
without administering a test dose. Thus, IV iron is becoming
available in safer formulations that are administered in a
more time-efficient fashion as a high dose infusion (Table 3).ell (iron carboxymaltose and ferumoxytol) or alternatively,
olecules (iron isomaltoside 1000). The strongly bound iron in the
the blood, hence improving safety.
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Older generations of IV iron preparations required multiple
visits for full iron repletion (iron sucrose, iron gluconate) or
a prolonged duration of administration (4–6 h for HMWID,
LMWID). The safety and efficacy of HMWID was retrospec-
tively evaluated in 70 pediatric patients with IBD who
received 119 total dose infusions.74 The average increase
in Hb concentration was 2.9 g/dL, but the risk of hypersen-
sitivity reactions should urge clinicians not to use HMWID
anymore. Koutroubakis et al. reported total dose infusions
with LMWID in 50 patients with IBD with a 10% rate of ad-
verse events, most of them after the administration of the
test dose.75 Auerbach et al. published data on a total of 570
infusions of 1 g of LMWID in 250 mL normal saline over a
median time of 63 min [interquartile range: 60–66 min]
without premedication, but for which a test dose is still
required. The most common diagnoses were heavy uterine
bleeding among women (43.5%) and gastrointestinal bleed-
ing among men (33.3%). A total of 41 adverse events were
reported in 22 patients (5.6%), with six patients requiring a
decreased rate or temporary interruption of the infusion.
There were no anaphylactoid reactions and no serious ad-
verse events. Therefore, in countries where newer IV iron
formulations are not available or the cost of the new
formulations is a problem, the total dose infusion of LMWID
may be still a choice for treating IBD associated IDA.76
The new generation of IV iron preparations allows for
administration of much higher single doses up to 20 mg/kg
body weight with iron isomaltidose 1000 (max: 2000 mg) or
ferric carboxymaltose (max: 1000 mg), in a short time
(15–60 min; Table 3). Ferumoxytol can be administered at
doses of 510 mg in less than 1 min. However, in the current
package insert, the recent bolded recommendation for a
30 min observation time, as well as the need for a second
visit to complete dosing, eliminates some of the benefit of
the short infusion time.77 Additionally, ferumoxytol might
be problematic in patients with IBD because it can interfere
with MRI signals due to the paramagnetic nature of its iron
core.20
The omission of a test dose further improves the con-
venience of these new IV iron preparations and lowers costs
in terms of the time spent at the hospital, including treat-
ment and waiting time. Furthermore, travel for continuous
treatments can be reduced in addition to a reduction of
nursing and medical time as well reduced cost of adminis-
tration. For a total iron dose of 1000 mg, ferric carboxy-
maltose could provide significant saving when compared
with iron sucrose in IBD and surgery.68,78,79 Cost effective-
ness of total dose infusion has been shown in patients with
chronic kidney disease by calculated saved costs of around
$300 per patient per year. This suggests that total dose
infusion is a valuable tool for the efficient and cost effec-
tive treatment of patients with IDA in various therapeutic
areas.80
9. Safety of IV iron
IV iron is generally well tolerated. In patients with renal
disorders (chronic kidney disease, dialysis patients and high
risk groups such as transplant patients) IV iron has been usedsafely for the treatment of anemia for many years and has
been demonstrated not to increase mortality or affect
disease progression.81–84 IV iron is becoming increasingly
established for the treatment of ID and IDA in other medical
disciplines, i.e. gastroenterology, hematology, cardiology,
oncology, gynecology, and for pre- and postoperative use.
The acute safety differences among IV iron products are
small when given at the recommended doses.85,86 Moreover
safety of IV iron is better compared to that associated with
red cell transfusions. According to data from FDA (2001–
2003; 30×106 doses) the incidence of life-threatening
adverse drug events (ADEs), including deaths, associated
with the use of IV iron is much lower than that associated
with the use of allogenic blood transfusion.85,86
When HMWID is avoided, the incidence of serious adverse
events with the newer formulations is b1:200,000, thus far
less than would be expected in any series where oral iron
would be given to patients with IBD.87 HMWID in contrast to
low molecular weight iron dextran LMWID has an increased
rate of severe side effects and deaths due to anaphylactic
reactions and this was the clinical safety rationale for
development of new IV iron preparations. It is believed that
the immunogenicity of the carbohydrate per se increases the
risk of anaphylactoid or anaphylactic reactions hence a test
dose is required, which has been studied carefully in pa-
tients with renal disease.88
The newer IV iron preparations demonstrate potentially
much lower immunogenic activity than the old ones. There-
fore they are approved without requirement for a test dose,
indicating a minimal risk of anaphylactoid or anaphylactic
reactions. The construction of the newer IV iron prepara-
tions allows for a slow release of iron which minimizes the
risk of free iron toxicity even in high dose IV iron prepa-
rations, hence minimizing the risk for oxidative stress and
damage caused by lipid peroxidation to e.g. the liver.
Experimental data from Jahn et al. demonstrating free iron
levels, noted that there were low levels for all iron prep-
arations (b0.3%) using unbuffered saline.89 Interestingly,
when the experiment was performed using buffered 0.9%
NaCl solution at pH 7.4, the free iron content was below
the detection limit of the method (b0.002%) for iron
isomaltoside 1000, iron carboxymaltose and ferumoxytol.
Switching to standard saline, which does not contain a buffer
led to a 100 fold increase (b0.002% to 0.262%) in the content
of free iron in iron carboxymaltose. Hence the dialyzable
iron in iron carboxymaltose is sensitive to pH. The relevance
of this is unclear but it should be noted that dilutions of IV
iron formulations for drip infusion are prepared in non
buffered physiological saline solutions. Reassuringly howev-
er for the clinician administration of 1000 mg iron dose
represents the release of a maximum of 2.62 mg of free iron
over 24 h, which amounts to only 40% of the capacity of
transferring to bound iron, such that the probability of
increasing free iron in the blood seems low. Nevertheless,
more studies on long-term safety of the newer IV iron prep-
arations are warranted and data are needed to examine
whether there is a variation in tissue iron deposition and
toxicity. IV iron has been used for more than twenty years by
nephrologists in chronic kidney disease and is a well
established entity in patient care for chronically ill patients
among nephrologists. Thus, the potential concern of iron
overload due to IV iron therapy appears hypothetical.
438 W. Reinisch et al.In patients suffering from chronic kidney disease the
beneficial role of IV iron is confirmed by being associated
with a lower rate in morbidity, hospitalization, and mortality
compared to patients not receiving IV iron. Perioperative
infusion of IV iron has been demonstrated to significantly
lower the need for transfusions and to lower the postoper-
ative rate of infections.84
10. Summary
Iron deficiency anemia is a frequent complication of IBD
which impressively adds to its morbidity. Awareness of
gastroenterologists needs to be increasingly directed to the
diagnosis and treatment of iron deficiency in these patients.
With the new generation of IV iron compounds a safe and
highly efficient treatment has become available and should
help to overcome the reservation of gastroenterologists to
replenish deficient iron stores in patients with IBD according
to existent guidelines. Improved tolerability and patient
convenience by rapidly restoring depleted iron status of
patients with IBD has been demonstrated.
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